This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Tam, L-S Articles by Szeto, C-C Search for Related Content PubMed PubMed Citation Articles by Tam, L-S Articles by Szeto, C-C Social Bookmarking                         What's this?

Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus

Department of Medicine and Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, tamls_813{at}yahoo.com

E K Li

Department of Medicine and Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong

C-K Wong

Department of Chemical Pathology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong

C WK Lam

Department of Chemical Pathology, The Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong

C-C Szeto

Department of Medicine and Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong

Twelve systemic lupus erythematosus (SLE) patients with mild to moderate disease activity (SLEDAI of 6 and on prednisolone, 0.5 mg/kg/day) were included in a prospective, randomized, double-blind, placebo-controlled pilot study for 24 weeks. Six were randomized to receive oral leflunomide and six received placebo. Primary outcome of this study included the mean change of SLEDAI at 24 weeks. Secondary outcomes included the changes in proteinuria, complement levels, anti ds-DNA binding, and prednisolone dosage. The mean age of the 12 patients was 41 + 9 years, and the mean disease duration was 8.5 + 5.8 years. All were female except one patient. The disease activity of both groups of patients decreased significantly after six months of treatment (14.7 + 6.0 to 3.7 + 2.3 in leflunomide group, P ¹/4 0.028, and 9.7 + 3.4 to 5.2 + 4.1 in placebo group, P ¹/4 0.027). Reduction in the SLEDAI from baseline to 24 weeks was significantly greater in the leflunomide group than the placebo group (11.0 + 6.1 in the leflunomide group and 4.5 + 2.4 in the placebo group respectively, P ¹/4 0.026). Minor adverse events included transient elevation in ALT, hypertension and transient leucopenia. In summary, leflunomide was more effective than placebo in treating SLE patients with mild to moderate disease activity and was safe and well-tolerated.

Key Words: leflunomide • randomized controlled trial • systemic lupus erythematosus

Lupus, Vol. 13, No. 8, 601-604 (2004)
DOI: 10.1191/0961203304lu1067sr


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G K Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints Ann Rheum Dis, April 1, 2009; 68(4): 477 - 483. [Abstract] [Full Text] [PDF]

				S. Y. Yuen and J. E. Pope Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials Rheumatology, September 1, 2008; 47(9): 1367 - 1372. [Abstract] [Full Text] [PDF]

				H. Wang, T. Cui, F. Hou, Z. Ni, X. Chen, F. Lu, F. Xu, X. Yu, F. Zhang, X. Zhao, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study Lupus, July 1, 2008; 17(7): 638 - 644. [Abstract] [PDF]

				J. Martin, J. Ricart, J Alcacer, N Rausell, and G Arana Adalimumab-induced lupus erythematosus Lupus, July 1, 2008; 17(7): 676 - 678. [Abstract] [PDF]

				M. Sebastiani, D. Giuggioli, E. Vesprini, A. Caruso, and C. Ferri Successful treatment with leflunomide of arthritis in systemic sclerosis patients Rheumatology, September 1, 2006; 45(9): 1175 - 1176. [Full Text] [PDF]